Source: Field Trip Health
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • First dosings completed at the Royal Adelaide Hospital in Australia
  • Pre-clinical data suggests FT-104 has a potency and pharmacology similar to psilocybin
  • Objectives of the Phase 1 study include characterization of the safety, tolerability, pharmacokinetics and pharmacodynamic effects of FT-104
  • Field Trip Health is a global leader in the development and delivery of psychedelic therapies
  • Field Trip (FTRP) was down 0.85 per cent trading at C$1.16 as of 1:01 pm EDT

Field Trip Health (FTRP) has announced the first successful dosings in the Phase 1 Clinical Study.

The study is entitled “A Double-Blind, Randomized, Placebo-Controlled Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Single, Ascending, Subcutaneous Doses of FT-104 HCl In Healthy Volunteers.”

The study is being conducted at PARC Clinical Research at the Royal Adelaide Hospital in Australia.

Field Trip’s first molecule in development, FT-104, is a prodrug of 4-OH-DiPT, a synthetic serotonin-2A (5HT2A) agonist.

Pre-clinical data suggests FT-104 has a potency and pharmacology similar to psilocybin, but with a significantly shorter half-life of approximately three hours.

Based on the FT-104 pre-clinical profile projecting a reduced treatment burden, and promising results from the early psilocybin therapy studies1 conducted at leading academic centers, the company believes that FT-104 could provide a rapid, safe, and effective therapy for depression and other mental health conditions when delivered in conjunction with psychotherapy.

The key objectives of the Phase 1 study include characterization of the safety, tolerability, pharmacokinetics and pharmacodynamic effects of FT-104 over a range of doses.

Subjective measurements will include intensity, duration and feelings produced by the acute psychoactivity after administration of FT-104 or placebo.

The company anticipates reporting results from the study in Q4 2022.

Dr. Nathan Bryson, Field Trip’s Chief Scientific Officer, commented on the news.

Photo courtesy www.meetfieldtrip.com

“The first administration of a novel, proprietary molecule is a landmark step for our company and a key milestone in our progress to develop FT-104 as a therapeutic for depression. Already, we are planning to share our work and our vision on the development of FT-104 in treatment-resistant depression and postpartum depression with the FDA in order to obtain their guidance as we look toward Phase 2 studies in 2023.”

Field Trip (FTRP) was down 0.85 per cent trading at C$1.16 as of 1:01 pm EDT.

More From The Market Herald

" The Market Herald’s Weekly Cannabis Report. August 5, 2022.

1 | Top Story: High Tide Inc. (TSXV:HITI) acquires retail stores in B.C. and Alberta
Field Trip Health - CEO, Joseph del Moral.

" Field Trip (TSX:FTRP) receives conditional approval to list common shares of Field Trip Health & Wellness on the TSXV

The TSX Venture Exchange (TSXV) has issued conditional listing approval to Field Trip Health Limited (FTRP).

" Optimind Pharma (CSE:OMND) commences trading on the CSE

Optimind Pharma (OMND) will begin trading on the CSE under the ticker symbol OMND.